Protective role of Cop in Rip2/Caspase-1/Caspase-4-mediated HeLa cell death  by Wang, Xin et al.
1762 (2006) 742–754
www.elsevier.com/locate/bbadisBiochimica et Biophysica ActaProtective role of Cop in Rip2/Caspase-1/Caspase-4-mediated
HeLa cell death
Xin Wang a, Malini Narayanan a, Jean-Marie Bruey b, Dorotea Rigamonti c, Elena Cattaneo c,
John C. Reed b, Robert M. Friedlander a,⁎
a Neuroapoptosis Laboratory, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, LMRC 123, Boston, MA 02115, USA
b The Burnham Institute for Medical Research, La Jolla, CA 92037, USA
c Department of Pharmacological Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy
Received 14 March 2006; received in revised form 20 June 2006; accepted 21 June 2006
Available online 21 July 2006Abstract
CARD only protein (Cop) was recently identified as a protein with significant homology with the CARD of caspase-1. We have conducted
functional studies on Cop and report on its role as an inhibitor of cell death in a broad range of cell death paradigms. A notable exception in the
ability of Cop to inhibit cell death pertains to its inability to inhibit ER stress-mediated cell death. Furthermore, in addition to the known
interaction of Cop and caspase-1, we demonstrated a novel interaction of Cop with caspase-4. We propose that Cop's action to prevent TNF-α-
induced cell death may operate independently of the mitochondrial death pathway. Furthermore, Cop overexpression inhibits Bid cleavage. In
summary, Cop inhibition of cell death, at least to a certain extent, results from its interference with the activation of caspase-1 and caspase-4.
Understanding the mechanistic details modulating caspase cell death pathways should provide important information for the development of
therapies for diseases featuring aberrant caspase activation. Cop, as an inhibitor of an important apical caspase cell death axis, may provide a tool
for modulating pathological cell death.
© 2006 Elsevier B.V. All rights reserved.Keywords: Cop; Caspase-1; Caspase-4; Rip2; Apoptosis1. Introduction
Caspases, like most other proteases, are synthesized as
inactive precursor molecules (“zymogens”), and they become
active in response to molecular stimuli [1–3]. Aberrant caspase
activation can result in inappropriate cell death, and can thereby
contribute to a myriad of diseases. For example, neurodegen-
erative diseases result in part due to the inappropriate activation
of caspase-induced cell death pathways within neurons, e.g.,
Huntington's disease, ALS, Parkinson disease, or Alzheimer's
disease [4]. As is expected for enzymes that effect a critical, and
terminal event such as cell death, the activity of caspases is
tightly regulated by several endogenous activators and in-
hibitors [5].⁎ Corresponding author.Tel.: +1 617 525 7775; fax: +1 617 734 8342.
E-mail address: rfriedlander@rics.bwh.harvard.edu (R.M. Friedlander).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.06.015In addition to its prominent role in inflammatory pathways,
caspase-1 activation is an important event in a number of cell
death paradigms. Although the regulation of caspase-1 activa-
tion was characterized in immune cells, these findings may also
apply to the enzyme's action in the context of cell death. By
infecting Salmonella and Shigella in macrophages, pyroptosis
is currently named as a novel cell death mechanism mediated by
the unique activation of caspase-1 [6,7]. So far, three adaptor
molecules (Rip2, ASC and Ipaf) have been reported to mediate
the activation of caspase-1 [8–13]. In particular, the processing
of pro-caspase-1 to an active enzyme is accelerated by
association of the zymogen with Rip2 protein (also known as
CARDIAK and as RICK) [14–16]. Though it does not posses
intrinsic enzymatic activity, Rip2 assembles with pro-caspase-1
into a complex whose stereochemistry accelerates the proces-
sing of the latter protein via an induced proximity mechanism.
The two proteins interact via their homologous caspase re-
cruitment domains (referred to as “CARD”). This process is
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pseudo-ICE), a molecule that binds to both procaspase-1 and to
Rip2 via their CARD domains and prevents the two proteins
from assembling into the aforementioned complex. Indeed, Cop
protein was identified by its high homology (92% amino acid
identity) to the CARD domain of procaspase-1 [8,9]. Rip2 binds
to the caspase-1 prodomain and participates in caspase-1
activation. Binding of Cop to the CARD-containing prodomain
of pro-caspase-1 inhibits caspase-1 activation, a model
formulated from work on inflammatory pathways [8]. ICE-
BERG and INCA are additional proteins with a high degree of
homology with the CARD-containing prodomain of pro-
caspase-1 [17,18]. Like Cop, ICEBERG and INCA are likely
to function as inhibitors of caspase-1-mediated inflammatory
pathways.
ASC (apoptosis-associated speck-like protein containing a
caspase recruitment domain) and Ice-protease activating factor
(Ipaf)/CLAN (caspase-associated recruitment domain, leucine-
rich repeat, and NACHT-containing protein)/CARD12 are the
other two adaptors of caspase-1, they also promote caspase-1
activation [10–13]. However, unlike Rip2, which directly binds
to Cop, there is no evidence that ASC or Ipaf/CLAN bind Cop.
In the current study, we therefore focused on the protective role
of Cop in Rip2 mediated caspase-1 related cell death pathways.
Caspase-1 plays an important role in pathological cell death,
particularly in neurologic diseases [4,19–26]. We have recently
demonstrated that Cop plays a critical role in inhibiting caspase-
1-mediated neuronal cell death [27]. We now evaluate whether
Cop can inhibit cell death other than that evaluated in neurons.
In the current work, we demonstrate that Cop inhibits TNF-α-,
hypoxia-, UV-, and staurosporine-mediated cell death. There-
fore, our results provide evidence for a role for Cop in a broad
spectrum of cell death paradigms. A notable exception to its
protective properties, Cop does not appear to play a significant
role in cell death pathways triggered secondary to endoplasmic
reticulum (ER) stress pathways. Furthermore, we demonstrate
that in addition to binding and inhibiting caspase-1 activation,
we demonstrate that Cop also binds and inhibits caspase-4
activation. Our data provide further insight into the mechanisms
regulating the activation of caspase-1 in cell death contexts.2. Materials and methods
2.1. Reagents and antibodies
The following reagents and antibodies were purchased from the indicated
suppliers: LipofectAMINE from Life Technologies; ApoAlert caspase-8
fluorescent assay kit including caspase-8 substrate Ac-IETD-AFC from
Clontech; caspase-1 substrate Ac-YVAD-AFC, caspase-2 substrate z-
VDVAD-AFC, caspase-4 substrate Ac-LEVD-AFC, caspase-5 substrate Ac-
WEHD-AFC, and caspase-9 substrate Ac-LEHD-AFC, and cycloheximide from
Calbiochem; caspase-3 substrate Ac-DEVD-AFC from PharMingen; caspase-10
substrate Ac-AEVD-AFC from Biovision; tumor necrosis factor-α (TNF-α)
from Roche; Thapsigargin, Tunicamycin, Brefeldin A, β-actin antibody, and
anti-mouse IgG fluorescein isothiocyanate conjugate (Fc-specific) from Sigma;
caspase-1 antibody from Santa Cruz; caspase-3, caspase-8 and cytochrome c
antibodies from PharMingen; caspase-4 antibody from Imgenex; caspase-5 from
Biomol; caspase-9 antibody from Zymed Laboratories; Bax antibody from Cell
Signaling; Bid antibody from Biocarta; Rip2 antibody from Alexis; Copantibody from Novus Biologicals; AIF antibody from QED Bioscience;
secondary antibodies and ECL reagents from Amersham Pharmacia Biotech;
Rh123 and Hoechst 33342 from Molecular Probes; LipofectAMINE and
LipofectAMINE 2000 from Invitrogen; human IL-1β immunoassay from R&D
Systems; and LDH assay from Roche.
2.2. Cell lines, constructs and transfections
Human cervical carcinoma HeLa cells, HEK293T cells, and Cos cells were
cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal
bovine serum, 0.1 mM nonessential amino acids, 2 mM L-glutamine, and
penicillin/streptomycin in 5% CO2 at 37 °C. All plasmids used were verified by
expression in Cos cells or HEK293T cells. ST14A cells are striatal neurons
conditionally immortalized by transfection with a temperature-sensitive form of
the simian virus 40 large T-antigen [28]. Mutant-htt ST14A cells are the ST14A
cells stably expressing a mutant huntingtin truncation (N548 mu), mutant-htt
ST14A cells have been used as a cellular model of Huntington's disease
[27,29,30]. Caspase-1 knock out ST cell lines (Caspase-1 KO ST) and wild type
ST cell lines (WT ST) are created from embryos of caspase-1-deficient mice and
wild type mice respectively (unpublished data). Caspase-1 KO ST cells, WT ST
cells, and mutant-htt ST14A cells were cultured in Dulbecco's modified Eagle's
medium supplemented with 10% fetal bovine serum, 0.1 mM nonessential
amino acids, 2 mM L-glutamine, and penicillin/streptomycin in 5% CO2 at
33 °C. For Cop stable HeLa cell line generation, Cop-encoding plasmids or
empty vectors were transfected in HeLa cells. Cop transfectants were selected by
growth in G418 (0.8 mg/ml) and screened for expression by immunoblotting.
Transient transfection was performed by LipofectAMINE in HeLa, and Cos
cells; and SuperFect (Qiagen) in HEK293T cells. EGFP–Cop plasmids were
constructed by Biomyx Technology, CA. The sequences were verified by DNA
sequencing.
2.3. Cell death induction
Cop and control-transfected stable HeLa cells, and striatal cells were
stimulated with various cell death inducers, including 10 ng/ml TNF-α+10 μM
CHX, 100 μM staurosporine, 20 and 100 μM Thapsigargin, 5 μg/ml
Tunicamycin, or 10 μg/ml Brefeldin A for 18 h. For UVC induction, HeLa
cells were rinsed in phosphate-buffered saline (PBS) and then irradiated
120 second with UVC (80 J/m2) in a minimal volume (50 μl/per well in 96 well-
plate) of PBS before culture medium was re-added. For hypoxia, Cop and Mock
HeLa transfectants were placed in a hypoxia chamber for 18 h with GasPakPlus
(Becton Dickinson). Cell viability was assessed by MTS assay.
2.4. MTS assay
The assay was performed as described previously [30] and according to the
manufacturer's instructions (Promega). Cells were treated or untreated, or cells
were transiently transfected with the indicated plasmids for the indicated hours.
Combined MTS/PBS solution was added, and the cells were placed into the
incubated for 1 h. The cells were then evaluated in a spectrophotomoter
(490 nm).
2.5. Microscopic determination of cell death
HeLa cells were co-transfected with indicated plasmids and GFP as the
transfection marker, or GFP-tagged Cop plasmids. After 24 h transfection,
transfected green cells were scored by chromatin condensation and nuclear
fragmentation under fluorescence microscopy. Images were taken with a Nikon
ECLIPSE TE 200 fluorescence microscope and processed by using IP LAB
software (Spectra Services, Webster, NY).
2.6. DNA fragmentation assay
HeLa stable cells were harvested by DNAZol (MRC). DNAwas purified by
EtOH precipitation. The precipitate was dissolved in H2O, digested for 30 min at
37 °C with 20 μg/ml DNase-free RNase, and analyzed by electrophoresis on a
1% agarose gel.
744 X. Wang et al. / Biochimica et Biophysica Acta 1762 (2006) 742–7542.7. Western blot analysis
Cop and Mock HeLa transfectants treated or untreated with 10 ng/ml TNF-
α+10 μM CHX were collected in lysis buffer (20 mM Tris, pH 8.0, 137 mM
NaCl, 10% glycerol, 1% Nonidet P-40, 2 mM EDTA with 5 mM Na2VO4,
protease inhibitor mixture [Roche], and 0.2 mM phenylmethylsulfonyl fluoride)
on ice, centrifuged at 15,000 rpm for 10 min at 4 °C. The protein content of the
extracts was measured (Bio-rad), and the sample (50 μg/lane) was analyzed by
western blotting.
2.8. Cell and tissue cytosolic fractionation
The preparation of cell cytosolic fractions was performed as described [31].
In brief, Cop and Mock HeLa transfectants treated or untreated with 10 ng/ml
TNF-α+10 μM CHX were scraped from dishes using a rubber policeman and
homogenized in a Dounce homogenizer by 20 strokes on ice in a
homogenization buffer (10 mM HEPES, pH 7.4, 250 mM sucrose, 10 mM
KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT plus protease
inhibitor cocktail [Roche]), followed by 700×g centrifugation for 5 min at 4 °C;
the supernatant was centrifuged at 15,000×g for 25 min at 4 °C and used as the
cytosolic component, and the produced pellets were lysed with RIPA buffer for
10 min on ice, and the supernatant was added to the sample buffer to obtain the
membrane fraction containing mitochondria and other organelles.
2.9. Co-immunoprecipitation and immunoblotting
Cells were collected in lysis buffer (25 mM HEPES, pH 7.6, 150 mM NaCl,
1 mM EDTA, 0.1% NP40, 10% glycerol, and a protease inhibitor mixture) and
lysed by immunoprecipitation (IP) or directly analyzed by western blot (WB).
For IP, the lysates incubated with an HA antibody bound to protein A/G-agarose
beads (Covance), and immune complexes were recovered by centrifugation,
followed by extensive washes, and then boiled in sample buffer. Eluted proteins
were separated by SDS-PAGE, transferred to nitrocellulose membranes, and
incubated with primary antibody conjugated with horseradish peroxidase. For
WB, the total lysates were resolved by SDS-PAGE and immunoblotted with
anti-FLAG-peroxidase (Sigma), anti-HA-peroxidase (Invitrogen), or anti-Myc-
peroxidase (Scant Cruz). Blots were developed using SuperSignal (Pierce) and
visualized by exposure to autoradiography film.
2.10. RNA interference assay
pU6-Cop siRNA plasmids were constructed by Biomyx Technology, CA.
Synthetic oligonucleotides with the following sequences were introduced into
pU6 vec to r : Cop S1 : 5 ′ - tg t ca AGGTATCGGACCTGCTGA-
GAGTCCtttttGTCTTCATCCTATCTAGACAT-3′ and 5′-ggaag AGGTATCG-
GACCTGCTGAGAGTCCAAACAAGGCTTTTCTCCAAGG-3′, Cop S2: 5′-
tgtca gtattctgaacatggcacctctgctttttGTCTTCATCCTATCTAGACAT-3′ and 5′-
ggaaggtattctgaacatggcacctctgcAAACAAGGCTTTTCTCCAAGG-3′. All
siRNA sequences were verified by DNA sequencing. Transient transfection of
pU6-Cop siRNA plasmids were performed by LipofectAMINE in HeLa stable
cells and mutant-htt ST14A cells. After transfection, HeLa cells were presented
for RT-PCR and western blot analysis, and mutant-htt ST14A cells were
presented for RT-PCR and western blot analysis as reported previously [27]. For
apoptotic induction, HeLa transfectants or mutant-htt ST14A cells were treated
by 2.5 ng/ml TNF-α+2.5 μM CHX for 18 h. For microscopic determination of
cell death, co-transfection with indicated plasmids and GFP as the transfection
marker, transfected green cells were scored by chromatin condensation and
nuclear fragmentation under fluorescence microscopy. Deconvoluted images
were taken with a Nikon ECLIPSE TE 200 fluorescence microscope and
processed by using IP LAB software (Spectra Services, Webster, NY). Cell
viability was assessed by MTS assay.
2.11. RT-PCR
Total RNA was isolated from HeLa cells using Trizol reagent (Invitrogen).
After reverse transcription, cDNA was amplified using PCR (Invitrogen). For
RT-PCR, the following primers were used: human Cop, 5′-GAAGACAGT-TACCTGGCAGA-3′ and 5′-TTGTATTCTGAACATGGCACC-3′ [8],
GAPDH, 5 ′ -ATGGTGAAGGTCGGTGTCAACGGA-3 ′ and 5 ′ -
TTACTCCTTGGAGGCCATGTAGGC-3′ (Clontech).
2.12. Caspase activity assays
Cop andMock HeLa transfectant extracts were prepared and caspase activity
assays were performed as described previously [30], according to the
manufacturer's instructions (Clontech). The following fluorogenic tetrapeptide
substrates were used: caspase-1-like Ac-YVAD-AFC, caspase-2-like z-
VDVAD-AFC, caspase-3-like Ac-DEVD-AFC, caspase-4-like Ac-LEVD-
AFC, caspase-5-like Ac-WEHD-AFC, caspase-8-like Ac-IETD-AFC, caspase-
9-like Ac-LEHD-AFC, and caspase-10-like Ac-AEVD-AFC. Released AFC
was quantified in a BioRad Versa Fluoro Meter (excitation at 400 nm and
emission at 505 nm).
2.13. Mature human interleukin-1β determination
Cop and Mock HeLa transfectants were treated with 10 ng/ml TNF-
α+10 μM CHX or untreated for 18 h. The supernatants were collected and
subjected to quantitative determination of human IL-1β concentrations
according to the manufacturer's instructions (R&D systems).
2.14. Statistical analysis
Densitometric quantification employed the Quantity one program (Bio-
Rad). Statistical significance was evaluated using t-test: p values <0.05 were
considered significant and are indicated by (*). **p values <0.001. All
experiments were repeated at least three times.
3. Results
3.1. Cop inhibits caspase-1/Rip2-mediated death of HeLa cells
To investigate the mechanism of action of Cop, we
expressed the Cop protein in HeLa cells and observe its
effect upon caspase-1/Rip2-mediated cell death. HeLa cells
are transiently transfected with DNA pro-caspase-1, Cop, or
Rip2. Similar to what we have demonstrated in neuronal cells
[27], transfection with either pro-caspase-1 or with Rip2
results in significant induction of cell death above what is
observed in control cells, co-transfection of pro-caspase-1 and
Rip2 results in a significant increase in cell death over either
construct individually, caspase-1/Rip2-mediated cell death is
almost completely inhibited, however, by transfection with the
Cop-encoding plasmid (Fig. 1A, B).
To better delineate the action of Cop in inhibiting the death of
HeLa cells, we also express a fluorescent EGFP–Cop fusion
protein in these cells and assess its ability to protect them from
pro-apoptotic stimuli (Fig. 1C–E). HeLa cells were transfected
with the plasmid encoding EGFP–Cop or with a control plasmid
that encodes GFP. Upon exposure to tumor necrosis factor-α/
cyclohexamide (TNF-α/CHX) stimulation, cells expressing
GFP control (recognizable by their green fluorescence) under-
went cell death, as evaluated using a viability assay (MTS), and
by morphologic criteria (cell shrinkage and chromatin con-
densation) (indicted by arrows in Fig. 1E, bottom left), as well as
by propidium iodide staining (similar results were obtained as
Fig. 1A, C, and E, data not shown). In contrast, cells expressing
the EGFP–Cop fusion protein demonstrate significant resistance
to TNF-α/CHX-mediated cell death (Fig. 1C–E).
Fig. 1. Transient overexpression of Cop protects against cell death. (A, B) HeLa cells are co-transfected with plasmids encoding Cop in combination with the indicated
expression plasmids encoding GFP, Rip2, pro-caspase-1 (C1). The amount of DNA is always brought to 2.05 μg by including empty vector pcDNA3. (C–E) HeLa
cells are transfected with 2.05 μg individual plasmids encoding GFP or GFP-Cop. After 24 h following incubation with TNF-α (10 ng/ml)+CHX (10 μM), apoptotic
and total transfected green cells are counted under fluorescence microscopy (A, C), and photomicrographs are recorded (E, arrows indicate the apoptotic cells). Cell
viability is measured in parallel by the MTS assay (B, D). (F) Caspase-1 KO ST 5–5 andWT ST 2 cells were incubated either with or without TNF-α (10 ng/ml)+CHX
(10 μM) for 18 h. Cell viability was then measured by the MTS assay. The results represent mean±S.D. of three independent experiments (**p<0.001, *p<0.05).(For
interpretation of the references to the colour in this figure legend, the reader is referred to the web version of this article.)
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amide (TNF-α/CHX) is widely used to induce apoptosis.
However, there is still no clear understanding of the cell death
pathways so activated or of the role of caspase-1 therein. We
have taken a genetic approach to elucidating the pertinent
molecular mechanisms. Cell lines are generated from striatal
explants from caspase-1-deficient and wild-type mice. Several
clones of such “ST cells” are established from animals of these
congeneic strains. The response of caspase-1 KO ST 5-5 and
that of WT ST 2, clones representative of the two categories, are
shown in Fig. 1F. Upon treatment with TNF-α/CHX, a
significantly smaller extent of cell death is observed for cells
deficient for caspase-1 than for wild-type controls (Fig. 1F). The
simplest explanation for this phenomenon is that activation of
caspase-1 is central to TNF-α/CHX-mediated cell death.
3.2. Cop inhibits cell death induced by several cell death
stimuli
To evaluate in further detail the mechanism of Cop-mediated
inhibition of cell death, we constructed HeLa cell lines stably
transformed with either a vector containing the gene for Cop-
FLAG or the empty vector as a control. Expression of the
FLAG-tagged Cop protein was detected by immunoprecipita-
tion and western blotting with an anti-FLAG antibody. Among a
dozen G418 resistant/Cop-expressing cell lines, Clone #2 andClone #11 were selected because they express high levels of the
heterologous protein (Fig. 2A). Clone #12 has incorporated the
vector, as indicated by its resistance to G418, but it expresses
Cop at a low level. Two other clones, Mock #1 and Mock #2 are
controls that have incorporated empty vectors (Fig. 2A). In
addition to their ease for manipulation, HeLa cells were selected
for these studies due to the fact that we could not detect
endogenous Cop in these cells.
To gain further insight into the mechanisms of Cop-mediated
inhibition of cell death, Cop-expressing HeLa cells were
exposed to a variety of cell death stimuli. Control cell lines
(Mock #1 and Mock #2) are sensitive to irradiation with UVC
(Fig. 2B), hypoxia (Fig. 2C), treatment with staurosporine (Fig.
2D), or stimulation with TNF-α/CHX (Fig. 2E). Exposure to all
these diverse stimuli result in significant induction of cell death.
The stable expression of Cop protein in Clone #2 and Clone #11
effectively inhibited cell death in all these conditions.
**p<0.001 is observed when comparing either Cop #2 or
Cop #11 with either of the two Mock cell lines in Fig. 2B–E.
Clone #12, which express Cop at a lower level, is also resistant
to these cell death challenges, but to a lesser degree than are
cells that express high levels of the Cop protein. Cop #12
demonstrates intermediate/non statistically significant protec-
tion in Fig. 2B–E, *p<0.05. **p<0.001 is only observed in
Fig. 2D with lower concentration staurosporine induction. In
addition, lower concentrations of staurosporine (10 μM) and of
Fig. 2. Overexpression of Cop rescues HeLa cells from several death-inducing stimuli, but not from ER stressors. (A) Expression of the FLAG-tagged Cop plasmids is assayed by FLAG immunoprecipitation (IP) and
western blotting (WB) to confirm its presence in stable “Cop” lines and its absence in “Mock” lines. Cop #2, #11, #12 and Mock #1, #2 represent selected clones overexpressing the Cop construct or empty pcDNA3
vector, respectively. Arrows indicate Cop and L.C. (immunoglobulin light chain) bands. (B–E) Cop and Mock transfectants were treated with cell death inducers TNF-α (10 ng/ml)+CHX (10 μM) (B), UVC irradiation
(80 or 40 J/m2 for 120 s) (C), hypoxia (D), or 100 and 500 μM staurosporine (STS) (E) for 18 h. Cell death is evaluated by the MTS assay, and expressed as the percent observed with untreated cells. Results represent the
mean±S.D. of at least three independent experiments (**p<0.001, *p<0.05). Empty bars indicate cells without cell death inducers. Hatched and solid bars represent cells with indicated concentrations of cell death
inducers. (F) Cop and Mock HeLa transfectants are treated with TNF-α (10 ng/ml)+CHX (10 μM), DNA is extracted after the indicated times and analyzed by agarose gel electrophoresis (one of three experiments is
shown). (G–I) Cop and Mock HeLa transfectants are treated with ER-stressors, 20 and 100 μM thapsigargin (THG) (G), 5 μg/ml Tunicamycin (TUN) (H), or 10 μg/ml Brefeldin A (I) for 18 h. Cell death is evaluated by
the MTS assay. The results are the mean±S.D. of at least three independent experiments.
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similar protective effect of Cop (data not shown).
To determine whether Cop blocks the pathways of
programmed cell death, we evaluated DNA laddering, a
hallmark of that process [32]. Indeed, TNF-α/CHX-induced
DNA laddering in control cells (Mock #1 and Mock #2) but not
in Cop-expressing cells (Fig. 2F). In conclusion, in HeLa cells,
the stable expression of Cop protein blocks cell death induced
by a broad variety of stimuli.
3.3. Cop does not protect HeLa cells from ER stress-induced
cell death
Thapsigargin, tunicamycin, and brefeldin A induce cell death
by inducing stress on the ER [33]. ER stress results in several
signal transduction events that impinge on downstream cell
death pathways [34–36]. To investigate the potential role for
Cop in cell death mediated by ER-stress, each of these
pharmacological agents was used to treat Cop-expressing and
control HeLa cells. In contrast to the protective effective that
Cop provides against other cell death challenges, Cop did not
rescue HeLa cells treated with any of these three drugs (Fig.
2G–I). These data suggest that Cop inhibits cell death by
interfering with a pathway that is either more upstream or
alternatively parallel to the ER-stress cell death pathway.
3.4. RNAi-mediated Cop knockdown sensitizes Cop-transfected
HeLa cells to death stimuli
To confirm that the resistance to cell death exhibited by
the HeLa-Cop cell lines is due to the Cop transgene, we used
RNA interference (RNAi) to knockdown its expression. We
used two RNAi vectors to knockdown Cop. One (pU6-Cop-
S2) proves highly effective at reducing levels of Cop mRNA
and protein. A second vector (pU6-Cop-S1) is ineffective and
serves as a control (Fig. 3A). HeLa-Mock cells serve as an
additional control, as they do not express detectable Cop (Fig.
3A, upper panel). Cop mRNA and protein were clearly
detected in HeLa-Cop cells. Both RT-PCR and immunoblot
analysis demonstrated that expression of Cop mRNA and
protein is significantly reduced following transient transfec-
tion of HeLa-Cop cells with the pU6-Cop-S2 siRNA vector
(Fig. 3A, lower panel) (transfection efficacy ∼80–90%).
RNAi-mediated reduction of Cop levels correlated with
increased sensitivity of HeLa-Cop cells to challenge with
TNF-α/CHX (Fig. 3B). Consistent with their undiminished
level of Cop expression, pU6-Cop-S1 siRNA-transfected
HeLa-Cop cells remained resistant to treatment with TNF-α/
CHX (Fig. 3B). As the knockdown of Cop expression by
RNA interference negates the transgene's protective effect, we
conclude that it is indeed the Cop protein that protects HeLa
cells from apoptotic induction in the stable transformants.
This conclusion is further strengthened by experiments
evaluating Cop loss of function by RNA interference in
mutant-htt ST14A cells (a cell type with endogenous Cop
[27]. Cop knock-down by pU6-Cop-S2 siRNA in mutant-htt
ST14A cells results in significantly increased vulnerability toTNFα/CHX-mediated cell death (Fig. 3C). We also have
previously demonstrated that Cop knock-down by RNA
interference results in increased vulnerability to mutant-htt
ST14A striatal cell death upon exposure to an apoptotic
stimulus [27].
3.5. Cop interacts with caspases-1 and -4, but not with
caspases-2, -3, -5, -8, -9 and -12
CARD–CARD interactions can promote or suppress the
activation of CARD carrying caspases, thereby mediating
apoptotic or anti-apoptotic signaling [37,38]. Since Cop
interacts with pro-caspase-1 and with Rip2 by such a
mechanism [8,9], we have evaluated possible interactions
between CARD-containing Cop and pro-caspases both with
and without that protein module. In agreement with
previously published data, co-immunoprecipitation/western
blot analysis demonstrated that Cop interacts with CARD-
containing caspase-1 [8]. In addition to its documented
interaction with pro-caspase-1, we also observed that HA-Cop
binds to CARD-containing pro-caspase-4 (Fig. 4A). In
contrast, Cop did not bind to CARD-containing pro-
caspases-2, -5, -9, and -12, nor did it interact with non-
CARD-containing caspase-3, and -8, (Fig. 4A). The results of
these functional studies are consistent with comparisons of the
amino-acid sequences of these proteins, in that the pro-
caspases whose CARD domains display the highest degree of
sequence homology with Cop are pro-caspase-1 (88.2%), and
pro-caspase-4 (25.9%) (Fig. 4B).
3.6. Cop inhibits the release of IL-1β and cell death mediated
by caspase-1/Rip2/caspase-4
Cop is induced during inflammation, presumably acting to
moderate caspase-1 activation and caspase-1-mediated IL-1β
processing after an initial bust of activity [8]. Because Cop
interacts with caspase-1 and -4, and caspase-1 plays a very
important role in TNF-α/CHX-mediated cell death (Fig. 1F),
consequently, we have evaluated whether Cop overexpression
inhibits caspase-1 and-4 activation following challenge with
TNF-α/CHX. Following addition of TNF-α/CHX to HeLa-
Mock #1 and HeLa-Cop #2 cells, caspase-1 and -4 activation
was measured by an enzyme assay using semi-specific
fluorogenic tetrapeptide substrates. Under these conditions,
caspase-1 is activated to ∼6-fold and caspase-4 is activated to
∼10-fold above the level observed in untreated HeLa-Mock
and HeLa-Cop lines which is defined as 1-fold. In contrast,
Cop-expressing stable transformants demonstrated inhibition of
caspase-1 activation following TNF-α/CHX treatment (Fig. 5A,
**p<0.001). In agreement with the fluorogenic assays,
immunoblot analysis of TNF-α/CHX-treated HeLa cells
revealed proteolytic processing of caspase-1 and caspase-4 in
Mock transfectants but not in Cop-expressing cells exposed to
TNF-α/CHX (Fig. 5B).
Caspase-1 is key in the physiologic cleavage of pro-IL-1β
into its bioactive form, and therefore the release of mature IL-
1β serves as an indicator of caspase-1 activation [39–41]. We
Fig. 3. Cop knockdown results in increased vulnerability to cell death. HeLa stable cells (A, B) and mutant-htt ST14A striatal cells (C) are transfected with pU6-siRNA, or pU6-siRNA Cop S1 or pU6-siRNA Cop S2 and
co-transfected with GFP by LipofectAMINE. After 24 h following transfection, cells are either extracted for RT-PCR or lysed for immunoprecipitation with anti-Flag antibody-linked beads, and analyzed by immunoblot
with Flag antibodies (A). For apoptotic induction, transfected cells are treated with 2.5 ng/ml TNF-α+2.5 μM CHX for 18 h. The number of apoptotic green cells (those exhibiting chromatin condensation and nuclear
fragmentation under fluorescence microscopy) is divided by the total number of GFP-positive cells (B, C, lower panel). Cell viability is also assessed by MTS assay (B, C, upper panel). The internal control of GADPH
was shown. L.C. means light chain. Results are representative from three independent experiments. Quantification of cell death represents the mean±S.D., **p<0.001.
748
X
.
W
ang
et
al.
/
B
iochim
ica
et
B
iophysica
A
cta
1762
(2006)
742–754
Fig. 4. Cop interacts with caspase-1 and -4. (A) HEK 293Tcells are co-transfected with HA-tagged Cop plasmid and plasmids encoding Flag-tagged caspase-4 or myc-
tagged caspase-2, -3, -5, -8, -9, -12. Lysates are either immunoprecipitated (IP) with HA Ab and then immunoblotted with Flag or myc antibodies, or directly analyzed
by western blotting (WB) with the indicated antibodies to confirm expression of the plasmid. The blots are representative of three independent experiments. (B)
Multiple sequence alignment of Cop with CARD domains of caspase-1, -2, -4, -5 and -9 are performed using the Clustal W method. Identical amino acids are labeled
grey and the identity is shown.
749X. Wang et al. / Biochimica et Biophysica Acta 1762 (2006) 742–754have previously demonstrated that endogenously produced IL-
1β plays a role in cell death both in lethally challenged HeLa
cells and in primary sensory neurons under conditions of
serum withdrawal [42], and that inhibition of cleavage of pro-Fig. 5. Cop prevents caspase-1 and -4 activation and IL-1β secretion. HeLa transfec
fluorogenic assays (A), or by immunoblotting (B). Results in panel A represent the r
non-treated controls. Reprobing the same blot with a β-actin antibody controls for
experiments. For the mature IL-1β ELISA determination, HeLa transfectants are tre
ELISA assay specific for mature IL-1β (C). Data represent the mean±S.D. of at leaIL-1β and secretion of mature IL-1β are associated with
inhibition of cell death [43]. Using an ELISA assay specific
for the mature form of IL-1β, we have quantified the release
of the active cytokine into conditioned medium of TNF-α/tants are treated with TNF-α/CHX. Caspase-1 and -4 activity is evaluated using
ation of caspase activation of TNF-α/CHX treated HeLa cells as compared with
equal loading (B). The data and blots are representative of three independent
ated with TNF-α/CHX for 18 h, supernatants are collected and evaluated by an
st three independent experiments (**p<0.001 in panels A and C).
Fig. 6. Cop selectively prevents caspase activation. HeLa transfectants are
treated with TNF-α/CHX. Caspase-2, -3, -5, -8, -9, and -10 activity is evaluated
using fluorogenic assays (A), or by immunoblotting (B). Reprobing the same
blot with a β-actin antibody controls for equal loading (B). Data represent the
mean±S.D. of at least three independent experiments (*p<0.05, **p<0.001).
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TNF-α/CHX treatment induces caspase-1 activation, we
detected a >4-fold increase in the concentration of mature
IL-1β [43]. Moreover, the release of mature IL-1β was
completely inhibited in Cop-expressing cells (Fig. 5C,
**p<0.001). These data demonstrate that stable expression
of Cop protein inhibits both the activation of caspase-1 and the
release of mature IL-1β.
3.7. Cop blocks the activation of certain caspases
To gain further insights into the mechanism of Cop-
mediated inhibition of cell death, the activity of various
caspase enzymes were evaluated in both Cop-expressing and in
control HeLa cells challenged with TNF-α/CHX. Because the
fluorogenic assays for these activities are only semi-selective
[44], their results are referred to as “caspase-like” activities.
Caspase activities were measured 5 h after TNF-α/CHX
exposure, at which time we detected significant activation of
caspase-1, -2, -3, -8, -9, and -10, as compared with levels in
untreated control cells which is defined as 1-fold. We did not
detect caspase-5-like activating under these conditions. Cop
expression inhibited the induction of caspase-1-like, caspases-
3-like, caspase-8-like and caspase-10-like protease activity in
TNF-α/CHX-treated HeLa cells (Fig. 6A, B, *p<0.05,
**p<0.001). Cop did not inhibit caspase-2-like or caspase-9-
like activation. Analyses by immunoblotting the lysates of
TNF-α/CHX-treated HeLa cells yielded results consistent with
the fluorogenic assays. Namely, treatment with TNF-α/CHX
stimulated the proteolytic processing of caspases-1, -3, -8, -9,
and-10, but not of caspase-5. Furthermore, expression of Cop
protein inhibited the activation of caspase-1, -3, -8, and-10
(Fig. 6B). However, Cop expression did not significantly
inhibit caspase-9 proteolytic cleavage (Fig. 6B) (Our western
blots fail to identify processed caspase-2 (data not shown)).
The results of these western blot analyses and fluorogenic
assays, in which Cop was found to prevent the activation of
CARD-containing caspase-1 and-4, but not CARD-containing
caspases-2 and -9, are consistent with the results of these co-
immunoprecipitation experiments, in which Cop only interacts
with CARD-containing pro-caspase-1 and -4, but not binds to
CARD-containing pro-caspases-2, -5, -9, and -12 (Fig. 4A). We
therefore conclude that overexpression of Cop protein, either
directly or indirectly suppresses activation of multiple caspases
in TNF-α/CHX-treated HeLa cells.
3.8. Cop does not inhibit HeLa cell death by preventing the
release of apoptogenic factors from mitochondria
Cop expression does not significantly inhibit TNF-α/CHX-
mediated caspase-9 activation (Fig. 6). The classic mechanism
of caspase-9 activation consists of the release of cytochrome c
from the mitochondria with the consequent assembly of the
apoptosome from Apaf-1, cytochrome c, and pro-caspase-9 [1].
We have measured the release of these mitochondrial death
factors following TNF-α/CHX treatment of HeLa cells — both
Mock-transfected controls and Cop-overexpressing cells. Asexpected, TNF-α/CHX induced release of cytochrome c and
apoptosis inducing factor (AIF) from the mitochondria into the
cytosol of HeLa cells. Overexpression of Cop did not inhibit the
release of either protein (Fig. 7A).
To determine the upstream signals resulting in Cop-
independent release of mitochondrial factors, we evaluated
the effect of Cop expression on Bid cleavage and Bax
translocation. Cleavage of cytosolic Bid, although classically
reported to be mediated by caspase-8, can also be mediated by
caspase-1 [45,46] or caspase-3 [47]. Bid cleavage results in
the formation of truncated Bid (tBID). tBID translocates to the
mitochondria triggering the release of apoptogenic proteins
from mitochondria [45,48]. Given that caspase-1, -3, and-8 are
activated with differing kinetics in control HeLa cells
following exposure to TNF-α/CHX, we next evaluated
whether Bid cleavage occurs in this cell death paradigm.
Indeed, we detected generation of tBid following addition of
TNF-α/CHX to HeLa cells (Fig. 7B). tBid cleavage was
remarkably inhibited in Cop-stable HeLa cells. The time-
course of caspase-1, -3, and -8 activation, and of Bid
cleavage, as well as the caspase-inhibitory characteristics in
Cop-expressing cells, points to caspase-1 and caspase-3, and
not to caspase-8, are the likely mediators of Bid cleavage in
this particular model.
Given the dissociation between the ability of Cop
expression to inhibit Bid cleavage and not inhibit the release
of cytochrome c and AIF, we evaluated an alternate signal-
Fig. 7. Cop inhibition of HeLa cell death is independent of mitochondrial cell
death pathways. Cop and Mock HeLa transfectants are treated with 10 ng/ml
TNF-α+10 μM CHX for various times. Cell cytosol or mitochondrial fractions
are prepared and immunoblotted with antibody to cytochrome c (A), AIF (A),
Bid (B) or Bax (C). The same blot reprobed with a β-actin antibody or a Cox IV
antibody serves as a control for equal loading (one of three experiments is
shown).
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TNF-α treatment, TNFR-1 recruits the adaptor proteins RIP
and RAIDD. TNFR-1 recruits the adaptor proteins RIP and
RAIDD, that in turn recruit pro-caspase-2 to the TNFR-1
signaling complex [49]. It has been speculated that caspase-2
is required for translocation of Bax from cytosol to
mitochondria, since transfection with siRNA targeting
caspase-2 inhibits Bax translocation [50]. In turn, Bax
translocation triggers the release of mitochondrial proteins
that mediate cell death [51–53]. We observed that caspase-2
is activated in mock-transfected cells upon TNF-α/CHX
treatment and that Cop expression failed to inhibit caspase-2
activation.
Western-blotting experiments using cellular subfractions
were employed to reveal the status of Bax translocation in
Cop-expressing and control cell lines. In agreement with a
previous report [53], Bax translocated from cytosol to
mitochondria following the addition of TNF-α/CHX to mock-
transfected HeLa cells (Fig. 7C). Significantly, Bax transloca-
tion was not inhibited in Cop-expressing cells (Fig. 7C). These
results point to caspase-2 activation as a likely mediator of Bax
translocation-mediated release of mitochondrial cell death
factors. It is of interest to note that Cop does not inhibit
caspase-2 activation, Bax translocation, or the release of
cytochrome c and AIF, but it does significantly diminish the
extent of cell death. A plausible explanation is that initiation of
the cell death program in TNF-α/CHX-treated HeLa cells
requires the orchestrated activation of multiple caspase-
dependent pathways.4. Discussion
4.1. The inhibitory roles of Cop in caspase-1/Rip2-mediated
cell death
By studying cell death in several model systems, we have
amassed evidence for a functional role of Cop protein in
counteracting the cell death pathway by its modulation of
caspase-1 activation. We arrive at this conclusion following a
variety of complementary experiments, including Cop over-
expression (following both transient and stable transfection) and
knockdown of its heterologous expression by RNA interference
(RNAi). The fact that Cop is a CARD-only protein suggests that
it acts as a functional decoy, inhibiting the interaction between
pro-caspase-1 and the activator protein Rip2. Such interference
has been previously demonstrated in the pathway leading to
inflammation, but not in the context of cell death [8,9]. Aberrant
activation of caspase-1 is known to occur during a variety of
neurological diseases [4,20–26,46,54], and during inflamma-
tory responses such as in macrophages resulting in products of
cytokines and death of the host cells [7]. Though the resulting
proteolytic activity is believed to aggravate their symptoms, the
regulation (and dysregulation) of this enzyme activation
remains unclear. The data presented in this manuscript provided
further support for a role for Cop protein in cell death pathways
[6]. An understanding of Cop function may suggest novel
strategies for developing therapies for diseases caused by hyper-
active caspase-1.
4.2. Three pathways may coordinately manipulate Cop's
inhibition of caspase-1/Rip2/Caspase-4-mediated cell death
The evidence presented in this report is consistent with a
model in which three coordinated pathways, all of them
activated by TNF-α, trigger various events in the apoptotic
cascade. First, following its binding of TNF-α, the activated
TNFR-1 recruits two adaptor proteins: TRADD and TRAFs
(Fig. 8) [55,56]. Rip2, which is then recruited to the TNFR-1/
TRADD/TRAFs complex [15], binds pro-caspase-1 and forces
it into a stereochemistry favoring zymogen's activation [17].
Consistent with published data on caspase-1 activation during
inflammation, our data demonstrate that Cop interacts with pro-
caspase-1, inhibiting Rip2-mediated activation of caspase-1 and
thereby preventing cell death [8,14]. In addition, our results also
demonstrate that caspase-1 plays an important role in TNF-α/
CHX-mediated cell death (Fig. 1F).
The second pathway activated following TNF-α binding to
its receptor with resulting recruitment of adaptor proteins FADD
and TRADD is initiated by activity of caspases-8 [55–57] and
caspase-10, a caspase homologous to caspase 8 [58] (Fig. 8).
Activated caspase-8 and-10 may in turn activate other
proteolytic enzymes, such as caspase-1 and-4 and the down-
stream caspase-3, -6, and -7, which ultimately cause cell death
[1,2]. The fact that caspase-10 is partially inhibited in Cop-
expressing cells suggests that a Cop-inhibitable caspase (i.e.,
caspase-1 or -4) may directly or indirectly affect the amplifica-
tion of caspase-10 activation.
Fig. 8. Model of signal transduction pathways involved in TNF-α-induced cell death. Following ligand binding, TNFR1 triggers three parallel pathways. The path
focusing on the Cop/Rip2/caspase-1/caspase-4/caspase-3 axis is depicted in the center. Another pathway involves caspase-10/-8 (left). The mitochondrial pathway
involves caspases-2 and -9, Bax, cytochrome c (cyto. c)/Smac/AIF and is schematized to the right.
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recruitment of the adaptor proteins RAIDD and RIP, mediating
caspase-2 activation (Fig. 8) [49,56]. Activated caspase-2 is
reportedly involved in mediating Bax translocation to the
mitochondria, resulting in release of mitochondrial apoptogenic
factors [53]. In our experiments, we detected Cop-independent
caspase-2 activation, Bax translocation, and release of apopto-
genic factors. Notably, caspase-9 activation also occurred in a
Cop-independent manner. While Cop expression results in
moderate inhibition of caspase-9 activity, likely an indirect
result of the inhibition of other caspases activities in Cop-
expressing cells, it does not appear to suppress the TNFR/
RAIDD/caspase-2 pathway at a proximal step.
We have previously reported that following addition of TNF-
α/CHX, HeLa cells process pro-IL-1 β into the mature andactive cytokine [43]. Given that the cell has storage of pro-IL-1
β, it does not require to produce new protein to generate mature
IL-1 β, and therefore is not surprising that even in the presence
of CHX, the cell may generate mature IL-1β.
A newly-demonstrated function of Cop is its direct binding
to pro-caspase-4 (Fig. 4A). Caspase-4 has been shown to be
involved in the death receptor pathway [59]. In this study, we
demonstrate that Cop-mediated inhibition of cell death is
associated with inhibition not only of caspase-1 but also of
caspase-4 (Fig. 4). The protein association data presented above
are consistent with the degree of homology between Cop and
the CARD domains of caspases-1, -2, -4, -5, and-9. The two
CARD-containing caspases with the highest degree of sequence
homology with Cop are the caspase-1 CARD (88.2%), and
caspase-4 CARD (25.9%) (Fig. 4B). Furthermore, the gene
753X. Wang et al. / Biochimica et Biophysica Acta 1762 (2006) 742–754encoding Cop has been mapped to human chromosome 11q22,
the same chromosomal region where the pro-caspase-1 and-4
genes reside [8]. Taken together, the conclusion that Cop
directly interacts with caspase-1, -4, and Rip2, but not caspase-
2, -3, -8, -9 and -12 suggests that Cop/Rip2/caspase-1/caspase-4
axis likely plays an important role in the protective function of
Cop against TNF-α/CHX-induced HeLa cell death. Since Rip2
interacts only with caspase-1, and not with caspase-4, -2, and-9
[14], caspase-4 may be activated/cleaved by other caspases such
as caspase-1 or caspase-10. However, it is also possible that
caspase-4 directly associates with a TNFR-1 signaling complex.
Since caspase-4 acts upstream of caspase-3 [60], it appears
likely that the action of caspase-4 supplements and/or is
redundant with that of caspase-1 (Fig. 8).
It is evident from our data, that the concerted action of
several caspase pathways must be required for effective
induction of cell death. Even though some caspase pathways
are not completely inhibited, Cop overexpression results in
significant protection. This Cop-mediated protection from cell
death is striking in that it appears to occur even though
mitochondrial release of apoptogenic proteins occurs, which
can lead to caspase-independent non-apoptotic cell death. In
conclusion, enhancing our understanding of the functional role
of the Cop/Rip2/Caspase-1/Caspase-4 cell death axis should
allow for its potential therapeutic manipulation in diseases
demonstrating activation of this cell death pathway.
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